DOCSLIB.ORG

Prostaglandin H2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prostaglandin H2 Prostaglandin H2 Introduction..................................................................................................................1 Chemical structure.........................................................................................................2 Biosynthesis of prostaglandin H2 (PGH2) ..........................................................................3 Synthesis products of PGH2............................................................................................5 Prostaglandins in inflammation reactions...........................................................................6 Mechanism of action of Aspirin.........................................................................................7 Mechanism of action of Paracetamol (=Acetaminophen)......................................................8 Introduction The term prostaglandin was initially mentioned by Ulf von Euler in the 1935s when he considered the prostate gland to be the main place of synthesis of the lipid-like substance. Only later did this turn out to be wrong together with the idea of there being only one prostaglandin as prostaglandins are a group of oxygenated polyene fatty acids. Sune Bergström and Bengt Samuelsson first isolated two prostaglandins in cristalline form in 1962 and named them Prostaglandin E (PGE) and Prostaglandin F (PGF) according to their solvent characteristics. Five years later this research group was able to name a hypothetical eicosanoid (20-carbon acid) as a basic structure. In 1964 Van Dorp and Sune Bergström succeeded in synthesizing prostaglandins from fatty acids. As measurement methods were gradually getting better, over 14 different prostaglandins could be made out by Hamberg and Bengt until 1974. Prostaglandins are subdivided into three main groups. Series-1 prostaglandins (from gamma- linolenic acid) have many positive effects. For example, they decrease blood coagulation and have anti-inflammatory effects. Series-2 prostaglandins (from arachidonic acid) counteract series–1 prostaglandins, causing or increasing inflammations and blood coagulation and intensifying pain- perception. In the body, they induce the adequate measures to react to wounds or other injuries. Series – 3 prostaglandins (from eicosapentaenoic acid) reduce synthesis of series – 2 prostaglandins and are therefore often described as anti-inflammatory. Prostaglandin H2 – Damocles 2010 presentation and text by Tina Gadau, Patricia Gerdes, Chantal Jagow, Carmen Klein Chemical structure Name: Prostaglandin H2 Empirical formula : C20H32O5 Family: Eicosanoids IUPAC: (Z)-7-((1R,4S,5R,6R)-6-((S,E)-3-hydroxyoct-1-enyl)-2,3- dioxabicyclo[2.2.1]heptan-5-yl)hept-5-enoic acid CAS-number: 42935-17-1 molar mass: 352,46 g/mol Prostaglandins are a group of cyclic, oxygenated, unsaturated polyene fatty acids. They can be deduced from a basic structure, the 20-carbon fatty acid. In 1980 Corey proposed calling all derivates of fatty acids with 20 C- atoms eicosanoids. All prostaglandins have a cyclopentane ring substituted with two diphatic side chains of which one has a carboxyl ending. It is distinguished between an a-chain (containing the carboxyl) and a ω -chain. The nomenclature of the prostaglandins is based on the structure of the cyclopentane ring, the number of double bounds in the side chains and the steric orientation of the substituents on the cyclopentane ring. The letter following „PG“ describes the structure of the cyclopentane ring. All naturally occuring prostaglandins have the α-configuration on C-9. Thromboxanes (TX) are closely related structures that can analogously be deduced from a hypothetical „thrombane acid“. Nomenclature of thromboxane corresponds to that of prostaglandins. Many prostaglandins are derived from the under physiological conditions unstable, endoperoxide containing Prostaglandin H2. Apart from the endoperoxide, PGH2 contains two double bonds, an hydoxy-group, a carboxylic acid and five chiral centers. Prostaglandin H2 – Damocles 2010 presentation and text by Tina Gadau, Patricia Gerdes, Chantal Jagow, Carmen Klein Biosynthesis of prostaglandin H2 (PGH2 ) from arachidonic acid is carried out by prostaglandin-H-synthases (PGHS) There are two major forms of PGHS, the isoenzymes PGHS-1 and PGHS-2. Their structures are a little different and they have different regions of action but they catalyse the same reactions. COX-1 produces normal physiological prostaglandins while COX–2 is induced during inflammatory reactions. The PGHS enzymes include two active sites: the cyclooxygenase (COX) – region, where aracidonic acid is transformed to PGG2 as well as the peroxidase (POX) – region, where PGG2 is transformed to PGH2. The hydrophobic substrate (arachidonic acid) reaches the active site of the COX by passing through its hydrophobic channel. The cyclooxygenase of PGHS-1 is referred to as COX-1, whereas COX-2 is the cyclooxygenase of PGHS-2. COX-2's active site is slightly larger than COX-1's. COX takes place inside the enzyme while POX is situated at a heme- containing active site on the outside of PGHS. Reactions of COX during the transformation of arachidoncic acid to PGG2: Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition DANIEL L. SIMMONS, REGINA M. BOTTING, AND TIMOTHY HLA; PHARMACOLOGICAL REVIEWS Vol. 56, No. 3; Pharmacol Rev 56:387–437, 2004 Prostaglandin H2 – Damocles 2010 presentation and text by Tina Gadau, Patricia Gerdes, Chantal Jagow, Carmen Klein Phospholipase A2 releases arachidonic acid released from the cell membrane. Arachidonic acid then binds to the active site in the COX. It is oriented in a way that allows tyrosine (tyr 385), which becomes a tyrosyl radical once the enzyme is activated, to abstract hydrogen from C-13 of the arachidonic acid. Thus an arachidonic radical, localised at C11 and 9, is formed. This is where molecular oxygen attacks to form an endoperoxide. The radical at C15 is then attacked by another molecule of oxygen. Transfer of hydrogen from Tyr385 yields PGG2, while the tyrosyl radical is regenerated. At the peroxidase (POX) site PGG2 is reduced to PGH2. POX is essential for COX as a ferryl protoporphyrin IX radical cation (Fe4+ = OPP*+) is formed from the reducing agent Fe3+ . This is needed for the transformation of Tyr385 to its radical form Tyr 385*. http://www.chemistry.uwaterloo.ca/undergrad/courses/web_courses/chem434/CourseMaterials/slides/Eicosanoids.ppt , 24. Juni 2010 The endoperoxides PGG2 and PGH2 are very unstable under physiological conditions. Prostaglandin H2 – Damocles 2010 presentation and text by Tina Gadau, Patricia Gerdes, Chantal Jagow, Carmen Klein Synthesis products of PGH 2 There are a lot of important prostaglandins which are synthesized from PGH2. They can be found in the whole organism but their effects and reactions can be different depending on the tissue they are in. Therefore they are also used in medical treatment. Thromboxane A2 is basically synthesized in thrombocytes with the aid of TXA-Synthase. However TXA2 is quite unstable and hydrolyzes with a half-life of about 30 seconds to the biologically inactive but stable TXB2 which probably acts for extraction. If a vascular wall gets injured, thrombocytes will adhere to it and become activated. In this progress TXA2 will be discharged. It effects vasoconstrictive in the cardiovascular musculature and the blood circulatory/circulation decreases. In addition, it arranges an irreversible aggregation of the thrombocytes so that the blood vessel is closed by interlinked thrombocytes. Afterwards the blood clotting occurs. Prostacycline (PGI2) is the antagonist of TXA2. It is generated in the endothelial tissue by the PGI-Synthase. In the cardiovascular musculature prostacyclin operates vasilatory. Furthermore, it inhibits the aggregation of the thrombocytes and as a result the blood clotting. So it lowers e.g. the blood pressure. Based on this fact it is used in medicine to prevent acute blood vessel closing. Prostaglandin D2 appears especially in the brain and in the spinal marrow and is synthesized in nerve cells and mast cells. It causes the production of cAMP. Assumedly, it plays an important role in allergic reactions because it evokes bronchia constriction and distinctive inflammations. That is the reason why inhibitors of PGD2-receptors operate anti-allergic. Asthma patients have a PGD2-concentration in their bronchial secretion which is ten times higher than normal. Additionally, PGD2 lowers the body temperature and stimulates the sleep (in contrast to PGE2). The main area of Prostaglandin F2-alpha is the uterus. COX-2 is induced perinatal to the placenta. Consequently, PGF2-alpha will be synthesized. It causes contraction of the uteri musculature. For this reason it is used for abortion and the medical induction of labor. The active pharmaceutical ingredients Latanosprost, Bimatoprost and Travoprost, that are derived from PGF2-alpha, are used for the medical treatment of glaucoma. They expand the drain canals for the aqueous fluid in the sclera of the eyes. Also the contractivity of muscles of other organs can be influenced by PGF2-alpha. 15-Hydroxyprostaglandindehydrogenase inactivates prostaglandines. The decomposition happens predominantly in the lungs, the liver and the kidneys. For medical treatment prostaglandines are usually injected or applied as e.g. an inhalant, eye drops or gel. Prostaglandin H2 – Damocles 2010 presentation and text by Tina Gadau, Patricia Gerdes, Chantal Jagow, Carmen Klein Prostaglandins in inflammation reactions Prostaglandins
Load more

Recommended publications
  • Structure-Based Discovery of Mpges-1 Inhibitors Suitable For
    www.nature.com/scientificreports OPEN Structure-based discovery of mPGES-1 inhibitors suitable for preclinical testing in wild-type Received: 4 January 2018 Accepted: 9 March 2018 mice as a new generation of anti- Published: xx xx xxxx infammatory drugs Kai Ding1,2,3, Ziyuan Zhou1,2, Shurong Hou2, Yaxia Yuan1,2,4, Shuo Zhou1,2, Xirong Zheng2, Jianzhong Chen1,2, Charles Loftin2, Fang Zheng1,2 & Chang-Guo Zhan1,2,4 Human mPGES-1 is recognized as a promising target for next generation of anti-infammatory drugs without the side efects of currently available anti-infammatory drugs, and various inhibitors have been reported in the literature. However, none of the reported potent inhibitors of human mPGES-1 has shown to be also a potent inhibitor of mouse or rat mPGES-1, which prevents using the well-established mouse/rat models of infammation-related diseases for preclinical studies. Hence, despite of extensive eforts to design and discover various human mPGES-1 inhibitors, the promise of mPGES-1 as a target for the next generation of anti-infammatory drugs has never been demonstrated in any wild-type mouse/rat model using an mPGES-1 inhibitor. Here we report discovery of a novel type of selective mPGES-1 inhibitors potent for both human and mouse mPGES-1 enzymes through structure-based rational design. Based on in vivo studies using wild-type mice, the lead compound is indeed non-toxic, orally bioavailable, and more potent in decreasing the PGE2 (an infammatory marker) levels compared to the currently available drug celecoxib. This is the frst demonstration in wild-type mice that mPGES-1 is truly a promising target for the next generation of anti-infammatory drugs.
    [Show full text]
  • AA Metabolism, 139 A2b1, 69, 70, 318–323 ABCB1 Gene, 176 Abciximab
    Index A aIIbb3, 60, 62, 69, 70, 73, 74, 79, 80 AA. See Arachidonic acid (AA) AJW202, 293 AA metabolism, 139 Akt-1, 345 a2b1, 69, 70, 318–323 Akt-2, 345 ABCB1 gene, 176 ALX-0081, 296 Abciximab, 206–208, 497, 500, 501, 504–505, ALX-0681, 298 509, 513, 514, 525 Anagrelide, 227, 229 approval, 206 Ankle brachial indexes (ABIs), 549, 587, EPIC trial, 207 595–597 EPILOG study, 207 framingham risk score, 551 EPISTENT study, 207 screening, 550 platelet binding, 207 sensitivity, 551 thrombocytopenia, 206 specificity, 551 in unstable angina, 208 vascular risk, 550 ABIs. See Ankle brachial indexes (ABIs) Antagomirs, 439 Acetylsalicylic acid (aspirin), 137–158 Antibodies, 317 ACS. See Acute coronary syndromes (ACS) Anticoagulants, 525, 537 Acute coronary syndromes (ACS), 288 Anticoagulation, 533, 534 Acute ischemic stroke, 143, 149–150 Antioxidant, 233 Acute myocardial infarction, 142, 143, 149, Antiplatelet agents, 263, 553 153, 157 Antithrombotic Trialist’s ADAMTS-13, 93 Collaboration, 553 Adenosine diphosphate (ADP), 37, 88, 96, aspirin, 553 166, 473 clopidogrel, 553 Adenosine triphosphate (ATP), 37 dipyridamole, 553 Adhesion, 90, 112–118, 125 meta-analysis, 560 Adhesion molecules infiltration, 264 picotamide, 553 Adiponectin, 315 risk reduction, 553 ADP. See Adenosine diphosphate (ADP) ticlopidine, 553 ADP inhibitors (or P2Y12 blockers), 497–499, vascular events, 553 501–505, 507–509, 513, 514 Antiplatelet therapy, 472 ADP-receptor antagonists, 169 Apixaban, 535, 539 Adverse effects, 153–156 Aptamers, 299–301 Aegyptin, 327 Arachidonic acid (AA), 474 P. Gresele et al. (eds.), Antiplatelet Agents, Handbook of Experimental 607 Pharmacology 210, DOI 10.1007/978-3-642-29423-5, # Springer-Verlag Berlin Heidelberg 2012 608 Index ARC1779, 299–300 TXS signaling, 279 ARC15105, 300 Cardiovascular death, 248 AR-C69931MX, 456 Carotid endarterectomy (ACE) inhibition, Aspirin, 474, 496, 498–499, 501–502, 143, 156 504–507, 511–514, 520, 522, Carotid stenosis, 523 527, 531, 533–537, 539, CCBs.
    [Show full text]
  • Antiluteogenic Effects of Serial Prostaglandin F2α Administration in Mares
    ANTILUTEOGENIC EFFECTS OF SERIAL PROSTAGLANDIN F2α ADMINISTRATION IN MARES Thesis Presented in partial fulfillment of the requirements for the Master of Science in the Graduate School of The Ohio State University Elizabeth Ann Coffman Graduate ProGram in Comparative and Veterinary Medicine The Ohio State University 2013 Thesis committee: Carlos R.F. Pinto PhD, MV, DACT; Dissertation Advisor Marco A. Coutinho da Silva PhD, MV, DACT; Academic Advisor Christopher Premanandan PhD, DVM, DACVP Copyright by Elizabeth Ann Coffman 2013 Abstract For breedinG manaGement and estrus synchronization, prostaGlandin F2α (PGF) is one of the most commonly utilized hormones to pharmacologically manipulate the equine estrous cycle. There is a general supposition a sinGle dose of PGF does not consistently induce luteolysis in the equine corpus luteum (CL) until at least five to six days after ovulation. This leads to the erroneous assumption that the early CL (before day five after ovulation) is refractory to the luteolytic effects of PGF. An experiment was desiGned to test the hypotheses that serial administration of PGF in early diestrus would induce a return to estrus similar to mares treated with a sinGle injection in mid diestrus, and fertility of the induced estrus for the two treatment groups would not differ. The specific objectives of the study were to evaluate the effects of early diestrus treatment by: 1) assessing the luteal function as reflected by hormone profile for concentration of plasma progesterone; 2) determininG the duration of interovulatory and treatment to ovulation intervals; 3) comparing of the number of pregnant mares at 14 days post- ovulation. The study consisted of a balanced crossover desiGn in which reproductively normal Quarter horse mares (n=10) were exposed to two treatments ii on consecutive reproductive cycles.
    [Show full text]
  • Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome
    International Journal of Molecular Sciences Review Role of Arachidonic Acid and Its Metabolites in the Biological and Clinical Manifestations of Idiopathic Nephrotic Syndrome Stefano Turolo 1,* , Alberto Edefonti 1 , Alessandra Mazzocchi 2, Marie Louise Syren 2, William Morello 1, Carlo Agostoni 2,3 and Giovanni Montini 1,2 1 Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Pediatric Nephrology, Dialysis and Transplant Unit, Via della Commenda 9, 20122 Milan, Italy; [email protected] (A.E.); [email protected] (W.M.); [email protected] (G.M.) 2 Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy; [email protected] (A.M.); [email protected] (M.L.S.); [email protected] (C.A.) 3 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Pediatric Intermediate Care Unit, 20122 Milan, Italy * Correspondence: [email protected] Abstract: Studies concerning the role of arachidonic acid (AA) and its metabolites in kidney disease are scarce, and this applies in particular to idiopathic nephrotic syndrome (INS). INS is one of the most frequent glomerular diseases in childhood; it is characterized by T-lymphocyte dysfunction, alterations of pro- and anti-coagulant factor levels, and increased platelet count and aggregation, leading to thrombophilia. AA and its metabolites are involved in several biological processes. Herein, Citation: Turolo, S.; Edefonti, A.; we describe the main fields where they may play a significant role, particularly as it pertains to their Mazzocchi, A.; Syren, M.L.; effects on the kidney and the mechanisms underlying INS. AA and its metabolites influence cell Morello, W.; Agostoni, C.; Montini, G.
    [Show full text]
  • Cyclooxygenase Pathway
    Cyclooxygenase Pathway Diverse physical, chemical, Phospholipase A Glucocorticoids inflammatory, and 2 mitogenic stimuli NSAIDs NSAIDs Arachidonic Acid Prostaglandin G2 CYCLOOXYGENASE Prostaglandin G2 Prostaglandin H Prostaglandin H Synthase-1 Synthase-2 (COX 1) (COX 2) Prostaglandin H2 PEROXIDASE Prostaglandin H2 Tissue Specific Isomerases Prostacyclin Thromboxane A2 Prostaglandin D2 Prostaglandin E2 Prostaglandin F2α IP TPα, TPβ DP1, DP2 EP1, EP2, EP3, EP4 FPα, FPβ Endothelium, Kidney, Platelets, Vascular Mast Cells, Brain, Brain, Kidney, Vascular Uterus, Airways, Vascular Platelets, Brain Smooth Muscle Cells, Airways, Lymphocytes, Smooth Muscle Cells, Smooth Muscle Cells, Macrophages, Kidney Eosinophils Platelets Eyes Prostacyclin Item No. Product Features Prostacyclin (Prostaglandin I2; PGI2) is formed from arachidonic acid primarily in the vascular endothelium and renal cortex by sequential 515211 6-keto • Sample Types: Culture Medium | Plasma Prostaglandin • Measure 6-keto PGF levels down to 6 pg/ml activities of COX and prostacyclin synthase. PGI2 is non-enzymatically 1α F ELISA Kit • Incubation : 18 hours | Development: 90-120 minutes | hydrated to 6-keto PGF1α (t½ = 2-3 minutes), and then quickly converted 1α Read: Colorimetric at 405-420 nm to the major metabolite, 2,3-dinor-6-keto PGF1α (t½= 30 minutes). Prostacyclin was once thought to be a circulating hormone that regulated • Assay 24 samples in triplicate or 36 samples in duplicate platelet-vasculature interactions, but the rate of secretion into circulation • NOTE: A portion of urinary 6-keto PGF1α is of renal origin coupled with the short half-life indicate that prostacyclin functions • NOTE : It has been found that normal plasma levels of 6-keto PGF may be low locally.
    [Show full text]
  • Vasoactive Responses of U46619, PGF2 , Latanoprost, and Travoprost
    Vasoactive Responses of U46619, PGF2␣, Latanoprost, and Travoprost in Isolated Porcine Ciliary Arteries Ineta Vysniauskiene, Reto Allemann, Josef Flammer, and Ivan O. Haefliger PURPOSE. To compare the vasoactive properties of the prosta- these responses can be modulated by SQ 29548 (TP-receptor noids U46619 (thromboxane A2 analogue), prostaglandin F2␣ antagonist) or AL-8810 (FP-receptor antagonist). (PGF2␣), latanoprost free acid, and travoprost free acid in isolated porcine ciliary arteries. METHODS. In a myograph system (isometric force measure- MATERIAL AND METHODS ment), quiescent vessels were exposed (cumulatively) to U46619, PGF , latanoprost, or travoprost (0.1 nM–0.1 mM). 2␣ Vessels Preparation Experiments were also conducted in the presence of SQ 29548 (TP-receptor antagonist; 3–10 ␮M) or AL-8810 (FP-receptor Porcine eyes were obtained from an abattoir immediately after death. antagonist; 3–30 ␮M). Contractions were expressed as the In cold modified Krebs-Ringer solution (NaCl 118 mM, KCl 4.7 mM, percentage of 100 mM potassium chloride-induced contrac- CaCl2 2.5 mM, K2PO4 1.2 mM, MgSO4 1.2 mM, NaHCO3 25 mM, tions. glucose 11.1 mM, and EDTA 0.026 mM), ciliary arteries were dissected 5 ␮ RESULTS. In quiescent vessels, contractions (concentration–re- and cut into 2-mm segments. In an organ chamber, two 45- m Ϯ tungsten wires were passed through the vessel’s lumen and attached to sponse curves) induced by (0.1 mM) PGF2␣ (87.9% 3.5%), U46619 (66.7% Ϯ 4.1%), and latanoprost (62.9% Ϯ 3.6%) were a force transducer for isometric force measurements (Myo-Interface; JP more pronounced (P Յ 0.001) than those induced by tra- Trading, Aarhus, Denmark).
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Activation of the Murine EP3 Receptor for PGE2 Inhibits Camp Production and Promotes Platelet Aggregation
    Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation Jean-Etienne Fabre, … , Thomas M. Coffman, Beverly H. Koller J Clin Invest. 2001;107(5):603-610. https://doi.org/10.1172/JCI10881. Article The importance of arachidonic acid metabolites (termed eicosanoids), particularly those derived from the COX-1 and COX-2 pathways (termed prostanoids), in platelet homeostasis has long been recognized. Thromboxane is a potent agonist, whereas prostacyclin is an inhibitor of platelet aggregation. In contrast, the effect of prostaglandin E2 (PGE2) on platelet aggregation varies significantly depending on its concentration. Low concentrations of PGE2 enhance platelet aggregation, whereas high PGE2 levels inhibit aggregation. The mechanism for this dual action of PGE2 is not clear. This study shows that among the four PGE2 receptors (EP1–EP4), activation of EP3 is sufficient to mediate the proaggregatory actions of low PGE2 concentration. In contrast, the prostacyclin receptor (IP) mediates the inhibitory effect of higher PGE2 concentrations. Furthermore, the relative activation of these two receptors, EP3 and IP, regulates the intracellular level of cAMP and in this way conditions the response of the platelet to aggregating agents. Consistent with these findings, loss of the EP3 receptor in a model of venous inflammation protects against formation of intravascular clots. Our results suggest that local production of PGE2 during an inflammatory process can modulate ensuing platelet responses. Find the latest version: https://jci.me/10881/pdf Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation Jean-Etienne Fabre,1 MyTrang Nguyen,1 Krairek Athirakul,2 Kenneth Coggins,1 John D.
    [Show full text]
  • Antiplatelet Effects of Prostacyclin Analogues: Which One to Choose in Case of Thrombosis Or Bleeding? Sylwester P
    INTERVENTIONAL CARDIOLOGY Cardiology Journal 20XX, Vol. XX, No. X, XXX–XXX DOI: 10.5603/CJ.a2020.0164 Copyright © 20XX Via Medica REVIEW ARTICLE ISSN 1897–5593 eISSN 1898–018X Antiplatelet effects of prostacyclin analogues: Which one to choose in case of thrombosis or bleeding? Sylwester P. Rogula1*, Hubert M. Mutwil1*, Aleksandra Gąsecka1, Marcin Kurzyna2, Krzysztof J. Filipiak1 11st Chair and Department of Cardiology, Medical University of Warsaw, Poland 2Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Center of Postgraduate Education Medical, European Health Center Otwock, Poland Abstract Prostacyclin and analogues are successfully used in the treatment of pulmonary arterial hypertension (PAH) due to their vasodilatory effect on pulmonary arteries. Besides vasodilatory effect, prostacyclin analogues inhibit platelets, but their antiplatelet effect is not thoroughly established. The antiplatelet effect of prostacyclin analogues may be beneficial in case of increased risk of thromboembolic events, or undesirable in case of increased risk of bleeding. Since prostacyclin and analogues differ regarding their potency and form of administration, they might also inhibit platelets to a different extent. This review summarizes the recent evidence on the antiplatelet effects of prostacyclin and analogue in the treatment of PAH, this is important to consider when choosing the optimal treatment regimen in tailoring to an individual patients’ needs. (Cardiol J 20XX; XX, X: xx–xx) Key words: prostacyclin analogues, pulmonary arterial hypertension, platelets, antiplatelet effect, thrombosis, bleeding Introduction tiproliferative effects [4]. The main indication for PGI2 and analogues is advanced pulmonary arterial Since 1935 when prostaglandin was isolated hypertension (PAH) and peripheral vascular disor- for the first time [1], many scientists have focused ders [5].
    [Show full text]
  • Medical Management of First-Trimester Induced Abortion and Miscarriage
    PACE REVIEW Medical management of first-trimester induced abortion and miscarriage Shamim Amis Jonathon Evans-Jones MRCOG FKCOG urgical evacuation is the mainstay of treatment in the effects of bleeding per vaginum, diarrhoea and vomiting. In UK for first-trimester termination of pregnancy and a randomised trial, where 1 mg versus 0.5 mg of gemeprost Smiscarriage and, although a niinor procedure, it has an was compared, the complete abortion rate was similar for associated considerable morbidity and mortality.' Induced the two groups (98-100%), although the incidence of abortion in the UK is now a safe procedure but on a global adverse effects was significantly lower in the latter group.'O scale continues to be a major cause of maternal mortality.2 Misoprosto1 is a synthetic analogue of prostaglandin E, and Medical management would provide a safe and effective causes increased uterine contractility with a low incidence of alternative. Many women would prefer to be given the other unwanted effects." The main advantages over choice and avoid the risks associated with anaesthesia and gemeprost are that it does not require refngeration, is cheaper surgery.l Recent studies have confirmed high acceptability and can be administered orally or vaginally. One gemeprost rates, showing that 8496% of women would choose pessary costs &22, whereas the equivalent dose of misoprostol medical treatment for a subsequent abortion." is just over The uterotonic properties are enkanced if women are pretreated with rmfepristone, reflecting the effect BACKGROUND of antiprogesterones in increasing sensitivity to prostaglandins. The drugs used for medically induced abortion in the UK When misoprostol is used in combination with mifepristone, include an antiprogesterone,mifepristone, and several prost- the vaginal route has been shown to be superior to the onl aglandin analogues, including gemeprost and misoprostol.
    [Show full text]
  • 2374 Supplementary Drugs and Other Substances
    2374 Supplementary Drugs and Other Substances 5. Burdock GA. Review of the biological properties and toxicity of Pharmacokinetics reduced to the endoperoxide prostaglandin H2 (PGH2). Prostag- bee propolis (propolis). Food Chem Toxicol 1998; 36: 347–63. Propylene glycol is rapidly absorbed from the gastrointestinal landin H2 is then converted to the primary prostaglandins pros- 6. Lieberman HD, et al. Allergic contact dermatitis to propolis in a tract. There is evidence of topical absorption when applied to taglandin D2, prostaglandin E2, and prostaglandin F2 , to throm- violin maker. J Am Acad Dermatol 2002; 46 (suppl): S30–S31. damaged skin. boxane A2 (TXA2) via the enzyme thromboxane synthetase, or 7. Giusti F, et al. Sensitization to propolis in 1255 children under- It is extensively metabolised in the liver primarily by oxidation to prostacyclin (PGI2) via the enzyme prostacyclin synthetase. going patch testing. Contact Dermatitis 2004; 51: 255–8. to lactic and pyruvic acid and is also excreted in the urine These products are further metabolised and rapidly inactivated in 8. Walgrave SE, et al. Allergic contact dermatitis from propolis. unchanged. the body. Dermatitis 2005; 16: 209–15. The secondary prostaglandins, prostaglandin A (PGA ), pros- 9. Majiene D, et al. Antifungal and antibacterial activity of propo- ◊ References. 2 2 lis. Curr Nutr Food Sci 2007; 3: 304–8. 1. Yu DK, et al. Pharmacokinetics of propylene glycol in humans taglandin B2 (PGB2), and prostaglandin C2 (PGC2) are derived during multiple dosing regimens. J Pharm Sci 1985; 74: 876–9. from prostaglandin E2, but are formed during extraction and Preparations 2. Speth PAJ, et al.
    [Show full text]
  • COX-1 and COX-2 Enzymes Synthesize Prostaglandins and Are Teacher Emeritus, University of Wisconsin-Madison) Mentor: Dr
    COX-1 And COX-2 Enzymes Synthesize Prostaglandins and Are Teacher Emeritus, University of Wisconsin-Madison) Mentor: Dr. David Nelson (Professor of Biochemistry, University of Wisconsin- (Student, University of Wisconsin-Madison) Center for Inhibited by NSAIDS (Nonsteroidal Anti-inflammatory Drugs) BioMolecular Madison West High School: Audra Amasino, Yuting Deng, Samuel Huang, Iris Lee, Adeyinka Lesi, Yaoli Pu, and Peter Vander Velden Modeling Advisor: Gary Graper, Teacher Emeritus, University of Wisconsin-Madison Mentors: Dr. David Nelson, Professor of Biochemistry, and Basudeb Bhattacharyya, Student, University of Wisconsin-Madison Abstract Prostaglandin Hormone Synthases (COX-1 and COX-2) are enzymes that produce prostaglandins. Prostaglandins are (1) Structure (3) Cyclooxygenase Active Sites responsible for fever, pain, and inflammation, but also the (5) Drugs maintenance of the lining of the stomach and prevention of In the pictures below, the heme is orange, the ulceration. COX-1 is found mainly in the gastrointestinal lining, hydrophobic knob is yellow, and the amino acids in the The three drugs below are all nonsteroidal anti- and COX-2 at sites of inflammation. NSAIDS (Nonsteroidal anti- Cyclooxygenase active site are colored in CPK (red for inflammatory drugs (NSAIDS). The first two NSAIDS, inflammatory drugs) such as aspirin, ibuprofen, naproxen, and oxygen, blue for nitrogen, and gray for carbon). aspirin and ibuprofen, are called nonselective Cox flurbiprofen inhibit both COX-1 and COX-2, and are taken inhibitors since they affect both COX-1 and COX-2 regularly by over 33 million Americans for pain and substantially (note their high COX-2/COX-1 effect inflammation. Some 10%-50% of these users suffer ratios).
    [Show full text]